Episode summary
Monday's Final Takeaways: LLY Foundayo Update & Lame Duck Congress Session Starts
Summary
Eli Lilly’s Foundayo program was the day’s standout company story, with late-stage data suggesting its weight-loss drug can also materially improve sleep apnea. The hosts said the phase 3 results showed fewer nighttime breathing interruptions, less oxygen deprivation, and roughly 11% body-weight loss over 52 weeks, with Lilly planning to submit the data to the FDA by the end of 2026. They also noted Lilly finished the session more than 4% higher.
The other major domestic theme was housing, where the market remained stuck between buyers who are priced out and sellers who are reluctant to cut asking prices. Realtor.com’s October report showed active listings up almost 7.5% year over year to nearly 1.18 million, while new listings fell 7.5% and only about 20% of sellers reduced prices. The national median list price slipped more than 2% to $415,000, but homes under contract dropped 10.5% as 30-year mortgage rates averaged 7.33%.
The hosts also focused on the start of the lame-duck Congress session, with government funding set to expire on December 11 unless lawmakers act. The expectation discussed was a temporary funding extension that would push the fight into the new Congress. On the macro side, they flagged China’s diverging price data and looked ahead to the next U.S. CPI report, which is expected to show slower monthly inflation.
Key takeaways
- The hosts said Lilly’s Foundayo data could open another market if the FDA filing happens by the end of 2026.
- The phase 3 program reportedly cut nighttime breathing interruptions by nearly 44% in patients not using breathing devices.
- Realtor.com data showed a frozen housing market: active listings rose nearly 7.5%, but new listings fell 7.5% and contracts dropped 10.5%.
- The hosts said only about 20% of sellers cut prices, helping keep the market stuck despite softer median list prices.
- The lame-duck Congress is expected to face a December 11 funding deadline, with a temporary extension viewed as the most likely outcome.
Notable quotes
“it can significantlyeduce the severity of sleep apnea in two late stage t”
“In this phase three program found a reduced nighttime breathing interruptions by nearly 44% in patients not using breathing devices”
“The d also reduced sleep related oxygen deprivation by as much as almost 56%, while patients lost roughly 11% of their body weight”
“Active listings are up almost 7.5% year over year to nearly 1.18 million homes”
“Mike does think that most likely the outcome is for hf funding, which then kicks the can down the road”
Topics
- nvidia investigation
- ai market movers
- eli lilly foundayo glp-1
- lame duck congress session
Companies and tickers mentioned
- NVDA
- LLY
- Nvidia
- Eli Lilly
Watch the episode
Watch “Monday's Final Takeaways: LLY Foundayo Update & Lame Duck Congress Session Starts” on YouTube
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Schwab Network
-
Jensen Huang Weighs Return as NVDA CEO; Risks & Rewards in 2027 CapEx Trade -
KG: "Shocked" by October Retail Sales; AI Chips Struggle as NVDA Drags -
NVDA Influence Beyond Tech: How Earnings Move VIX, Other Sectors -
The Big 3: SHOP, TMUS, S -
NVDA Earnings, Tighter AI Chip Restrictions to Test SPX Bulls -
How NVDA Earnings Will Move Wall Street; U.S. Tightens AI Chip Exports
Schwab Network, this episode and its artwork belong to their owners. Octagon is not affiliated with the show; this page is an independent summary.